Prolonged Stimulation of Pulsatile Growth Hormone Secretion via Therapeutic Affinity Complexation of GHRH Analogs in Human Subjects

CJC-1295 is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH). In the literature, its evaluation centers on the addition of DAC (Drug Affinity Complex), which binds to blood proteins to turn a short-lived signal into a long-lasting compound.

• Journal Context: The Journal of Clinical Endocrinology & Metabolism / Oxford Academic | Identifiers: DOI: 10.1210/jc.2005-1537 / PMID: 16332930

• Principal Investigators: Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., et al. (ConjuChem Inc., Montreal)

• Methodology: A randomized, double-blind, placebo-controlled human trial evaluating the pharmacokinetics and safety of CJC-1295. Healthy adult cohorts received varying subcutaneous doses to measure sustained increases in plasma GH and Insulin-like Growth Factor 1 (IGF-1) lines.

• Key Findings: A single administration of CJC-1295 induced a $4$-to-$10$-fold increase in mean plasma growth hormone concentrations, maintaining these elevated levels for up to 15 days. Simultaneously, baseline IGF-1 levels were expanded by $1.5$-to-$3$-fold, with the active window extending past two weeks. Crucially, the compound did not erase the body’s natural, pulsatile rhythm of GH release, proving that GHRH affinity complexation safely extends metabolic signaling.